metamucil and glp-1 Metamucil's Two-Week Challenge & its Benefits │ Metamucil® Fiber Therapy for regularity/fiber supplement An easy way to increase your daily fiber intake Metamucil 4-in-1 Psyllium Fiber Supplement

The tirzepatide group achieved a mean body-weight reduction of 18%, which appeared greater than that in the placebo group (45)

The way Tirzepatide works is by acting as a dual agonist

Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence

Gene Ther